World of DTC Marketing

APRIL 11, 2021

The CDC says “neither the recently authorized and recommended vaccines nor the other COVID-19 vaccines currently in clinical trials in the United States can cause you to test positive on viral tests , which are used to see if you have a current infection.? Plus, clinical trial settings aren’t always the same as real-world settings.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

pharmaphorum

JULY 6, 2021

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. ” The anti-HER2 market is advancing rapidly however, with a new generation of drugs coming through the industry pipeline.

Vaccination 119

Vaccination Vaccine Trials Antibody 119

Pharmaceutical Technology

AUGUST 24, 2022

The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1% Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. CAGR between 2020 and 2028.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Pharmaceutical Technology

SEPTEMBER 14, 2022

Successful TIL therapy depends on the infusion product containing tumour-reactive T cells that, on infusion, generate an anti-tumour immune response that causes disease regression. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

XTalks

DECEMBER 20, 2024

Steqeyma was evaluated through a comprehensive set of studies, including a Phase III trial that showed that the biosimilar met the primary endpoint of improved Psoriasis Area and Severity Index (PASI) scores by Week 12 and sustained results through Week 28. billion by 2034, driven by an 11.2 percent compound annual growth rate (CAGR).

FDA Approval 52

FDA Approval Immune Response Antibody Marketing 52

pharmaphorum

FEBRUARY 22, 2021

In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

Pharmaceutical Technology

JANUARY 19, 2023

The expanded manufacturing and marketing approval was based on the data obtained from the Phase II trial, conducted in Australia and the US; a separate Phase II trial held in South Africa; and the UK-sponsored COV-BOOST trial. It has been developed using the company’s recombinant nanoparticle technology.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. The ongoing double-blind trial measures the effect of adding REGN-COV2 to usual standard of care, compared with usual standard of care. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

XTalks

NOVEMBER 5, 2024

Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024. Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

pharmaphorum

DECEMBER 11, 2020

Interim results from a phase 1/2 clinical trial show the immune response from Sanofi/GSK’s vaccine produced a lower immune response in older adults. While antibody levels were comparable to those seen in recovering COVID-19 patients in adults aged 18-49, the response was lower in older adults.

Immune Response 72

Immune Response Trials Vaccination Vaccine 72

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “With new variants – like Omicron and B.1.640.2

Protein 126

Protein Vaccination Vaccine Immune Response 126

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma.

Antibody 98

Antibody Immune Response Vaccination Vaccine 98

World of DTC Marketing

AUGUST 3, 2020

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. What we have right now is a collection of animal data, immune response data, and safety data based on early trials and from similar vaccines for other diseases.

Vaccination 155

Vaccination Vaccine Immune Response Trials 155

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The vaccine works by inducing the body's immune response. Influenza vaccine 2 overview Vaccine is under development for the prevention of infections caused by pandemic influenza virus.

Production 100

Production Vaccination Vaccine Immune Response 100

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The vaccine works by inducing the body's immune response. Influenza vaccine 2 overview Vaccine is under development for the prevention of infections caused by pandemic influenza virus.

Production 100

Production Vaccination Vaccine Immune Response 100

The Pharma Data

JUNE 29, 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. In the UK, Vaxzevria is known as COVID-19 Vaccine AstraZeneca.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Delveinsight

JANUARY 22, 2021

The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. At present, there stands no treatment option that can cure the disease.

Marketing 65

Marketing Drugs Antibody Compliance 65

XTalks

OCTOBER 11, 2024

The vaccine uses recombinant RSV glycoprotein F, stabilized in its prefusion conformation (RSVPreF3), along with GSK’s AS01E adjuvant to boost the immune response — the same adjuvant used in Shingrix, its shingles vaccine, but at a lower dose. Nevertheless, GSK maintains its market lead. Efficacy over the entire study was 62.9

Vaccination 103

Vaccination Vaccine Immune Response Trials 103

pharmaphorum

DECEMBER 17, 2020

UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed where class rivals from Roche and Sanofi/Regeneron have failed. Primary outcome of the SILVAR study will be all-cause 28-day mortality. EUSA Pharma bought global rights to the drug from Janssen in $115 million.

Drugs 105

Drugs Immune Response Trials Clinical Trials 105

XTalks

JULY 28, 2021

The companies are set to go head-to-head in a high-stakes market battle involving billions of dollars — a battle Pfizer has been winning for over a decade now. The vaccine is currently being tested in children in Phase III trials and the company is hoping to get FDA approval by the end of the year.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

pharmaphorum

JULY 20, 2022

Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported a phase 3 trial of its lead gene therapy VB-111 for ovarian cancer failed a pivotal trial. ” The company’s fall into penny share ($0.44) territory from its year-long high of more than $2.50

Gene Therapy 98

Gene Therapy Gene Immune Response Antibody 98

Pharmaceutical Technology

MAY 2, 2023

The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Pharmaceutical Technology

DECEMBER 1, 2022

The GCC Vaccine is being analysed in Phase II clinical trials. It can induce immune responses against Guanylyl Cyclase C (GCC) expressing colorectal, pancreatic, gastric and oesophageal cancers. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Clinical Trials Clinical Trials Immune Response 130

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The new result suggests that REGEN-COV could be used much more broadly than at present. That was down from almost $2.6

Antibody 105

Antibody Vaccination Vaccine Immune Response 105

XTalks

SEPTEMBER 17, 2020

In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. IGF-1 is an acceptable surrogate endpoint in trials of growth hormone receptor agonists like Somavert, and is preferred for pediatric patient populations.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

JUNE 21, 2024

This is more than the approximately 52 percent covered by Pfizer’s Prevnar 20, which is the current pneumococcal vaccine market leader and the top player in the company’s pneumococcal vaccine portfolio. These numbers do not reflect the efficacies of the vaccines, which have not been compared head-to-head in any trial yet.

FDA Approval 108

FDA Approval Vaccination Vaccine Life Science 108

Camargo

DECEMBER 13, 2021

Like with small molecules, clinical trials of biologics are designed to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies. Product Type-Specific Analysis.

Development 161

Development Production Immune Response Licensing 161

XTalks

NOVEMBER 10, 2020

Update (November 10, 2020): Pfizer and BioNTech announced in a press release yesterday that their candidate COVID-19 vaccine was found to be more than 90 percent effective in preventing infection by the novel coronavirus in Phase III trials. The ongoing Phase III trial continues to evaluate the mRNA vaccine in close to 44,000 individuals.

Vaccination 75

Vaccination Vaccine Trials Clinical Trials 75

pharmaphorum

OCTOBER 5, 2021

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy patients. Initial results from that study were negative.

Antibody 111

Antibody Immune Response Vaccination Vaccine 111

pharmaphorum

APRIL 22, 2022

Ampio Pharma’s candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review. The question now is whether Ampio has the resources on hand to run a new study without raising additional funding.

Immune Response 111

Immune Response Trials Clinical Trials Clinical Trials 111

Pharmaceutical Technology

AUGUST 12, 2022

The concept behind this form of treatment is that the introduction of these cells will enhance the immune response to disease, often through bioengineering the immune cells to have improved functionality and characteristics, such as longer half-lives. Overall, the global CAR-T cell market for all indications was worth $1.7

Development 130

Development Drugs Immune Response Marketing 130

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US. Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

pharmaphorum

SEPTEMBER 15, 2020

The antibody – called lenzilumab – targets colony stimulating factor 2 (CSF2) and granulocyte-macrophage colony stimulating factor (GM-CSF), two cytokines that are linked to the runaway immune response that can result in serious lung damage in COVID-19. Roche meanwhile is continuing to trial its drug in combination with remdesivir.

Drugs 97

Drugs Antibody Contract Manufacturing Immune Response 97

pharmaphorum

AUGUST 16, 2020

ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and should be ready for first deliveries before the end of the year. It will be provided on a no-profit basis while the pandemic is ongoing. Those deals cover 200 million doses of J&J’s Ad26.COV2.S

Vaccination 111

Vaccination Vaccine Immune Response Trials 111